Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâ€™s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/09/26	US$1.834	+3.02%	109,866
15/09/26	US$1.780	+1.71%	230,622
14/09/26	US$1.750	+1.74%	69,174
11/09/26	US$1.720	+1.18%	393,645
10/09/26	US$1.700	+1.19%	9,491

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.780USD

Average target price

26.00USD

Spread / Average Target

+1,360.67%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX 01:41:10 17/09/2026 HKT			5-day change	1st Jan Change
1.850 ^USD	+3.93%		+9.15%	+0.75%

09-11	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
08-20	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI

Market Cap	8.53M 7.39M 6.99M 6.34M 11.89M 818M 11.96M 83.4M 32.23M 415M 32.04M 31.33M 1.32B	P/E 2027 *	-1.7x	P/E 2028 *	-2.05x
Enterprise Value	8.53M 7.39M 6.99M 6.34M 11.89M 818M 11.96M 83.4M 32.23M 415M 32.04M 31.33M 1.32B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	97.32%	Yield 2027 *	-	Yield 2028 *	-

09-11	Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026	CI
08-20	Alzamend Neuro Reports Resting-State Fmri Findings For Al001 Accepted For Poster Presentation At Neuroscience 2026	CI
08-18	Alzamend Neuro, Inc. Reports Phase 1/2A Lithium Imaging Data For AL001 At ISMRM Workshop	CI
08-05	Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending	CI
07-23	Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026	CI
07-22	Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt	CI
07-22	Alzamend Neuro, Inc. Announces Demise of Lynne Fahey Mcgrath, Director on July 20, 2026	CI
04-07	Alzamend Neuro, Inc. Reports Encouraging Pharmacodynamic Data From Phase II Clinical Trial Of AL001	CI
03-26	Alzamend Neuro, Inc. Reports Positive Topline Data From Phase II Clinical Trial of AL001	CI
03-16	Alzamend Neuro Initiates Phase Ii Clinical Trial of Al001 Lithium in Brain Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital	CI
03-16	Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital	RE
03-12	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026	CI
03-07	Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stock - SEC filing	RE

12/04/23	Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	MT
27/12/21	Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating	MT
01/10/21	Alzamend Neuro : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target	MT

Alzamend Neuro, Inc. Stock

Stocks

ALZN

US02262M6057

Biotechnology & Medical Research

Valuation: Alzamend Neuro, Inc.

Chart: Alzamend Neuro, Inc.

Latest news: Alzamend Neuro, Inc.

Analysts' recommendations: Alzamend Neuro, Inc.

Press Releases: Alzamend Neuro, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Alzamend Neuro, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

08-20	Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC	PR
08-18	Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain	PR
07-23	Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)	PU
04-07	Alzamend Neuro : Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital	PU
03-26	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions	PR

1 day	+3.93%
1 week	+9.15%
Current month	+14.61%
1 month	+16.06%
3 months	+43.26%
6 months	-12.68%
Current year	+0.75%

1 week	1.58	1.85
1 month	1.41	1.85
Current year	0.84	2.54
1 year	0.84	2.68
3 years	0.84	360.31
5 years	0.84	4,819.5
10 years	0.84	45,292.48

Manager	Title	Age	Since
Stephan Jackman CEO	Chief Executive Officer	50	20/11/2018
David Katzoff DFI	Director of Finance/CFO	64	05/08/2022
Henry Nisser LAW	General Counsel	57	01/05/2019

Director	Title	Age	Since
Todd Ault CHM	Chairman	56	26/02/2016
William Horne CHM	Chairman	57	01/06/2021
Stephan Jackman BRD	Director/Board Member	50	01/09/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/8/26	Todd Ault	Sell	Founder	-2,000	0.0417%
26/8/26	HYPERSCALE DATA, INC.	Other	Company	0	0%
31/7/26	HYPERSCALE DATA, INC.	Free	Company	7,500	0.1565%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZAMEND NEURO, INC.	+3.93%	+9.15%	-30.01%	-99.40%	8.53M
LONZA GROUP AG	+0.22%	+0.07%	-1.90%	+26.89%	45.81B
REVOLUTION MEDICINES, INC.	-3.26%	-4.51%	+343.65%	+541.16%	43.91B
IQVIA HOLDINGS INC.	+1.16%	+6.00%	+45.81%	+30.11%	44.39B
BEONE MEDICINES AG	+0.49%	-0.99%	+6.21%	+66.35%	39.4B
CELLTRION, INC.	-0.17%	-3.22%	+9.45%	+38.69%	31.26B
ASCENDIS PHARMA A/S	+2.65%	-5.56%	-	-	15.75B
MEDPACE HOLDINGS, INC.	-0.08%	+5.88%	+26.49%	+127.30%	17.32B
EUROFINS SCIENTIFIC SE	+1.66%	+5.30%	+19.25%	+35.77%	14.73B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.17%	+1.48%	+86.32%	+34.14%	13.03B
Average	+1.00%	-0.38%	+56.14%	+89.00%	26.56B
Weighted average by Cap.	+0.16%	-1.10%	+77.82%	+133.40%

	2027 *	2028 *
Net sales	-	-
Net income	-10.8M -9.36M -8.85M -8.03M -15.05M -1.04B -15.14M -106M -40.81M -526M -40.57M -39.67M -1.68B	-10.8M -9.36M -8.85M -8.03M -15.05M -1.04B -15.14M -106M -40.81M -526M -40.57M -39.67M -1.68B
Net Debt	-	-